Objective: to compare the treatment outcomes of injecting PRGF versus HA in patients with TMD following arthroscopic treatment .
Methods: A prospective, randomized clinical trial was conducted 12 patients diagnosed with TMD, underwent arthroscopic disc release. randomly divided into two groups Gp A: received HA & Gp B: received PRGF . Synovial samples were collected before and immediately prior to each injection measure levels of (IL-6) and(TNF-α) in each sample, and statistical analysis was conducted also pain levels were assessed using the Visual Analog Scale (VAS)
Results: In this study, the comparison of TNF-α levels between both groups revealed that TNF-α levels significantly higher in PRGF group compared to the HA group, indicating a more pronounced inflammatory response. While regarding comparison of IL-6 levels between both groups showed a slightly more significant decrease in the PRGF group, although this difference was not statistically significant. Regarding VAS between both groups there were significantly lower VAS scores at 2 weeks and 1 month compared to those receiving HA injections. While the PRGF group exhibited a marginally greater reduction in VAS scores overall, the difference was not statistically significant when compared to the HA group.
Conclusion: Both PRGF and HA injections appear to be effective adjuncts to arthroscopic treatment for TMJ disorders and alleviated pain. PRGF demonstrated superior efficacy in decreasing TNF-α levels and achieved greater pain reduction compared to HA throughout all follow-up periods. These findings highlight the potential of PRGF as a more effective therapeutic option for TMJ disc displacement management.